Doxylamine succinate

What it is

Doxylamine succinate is a first-generation (sedating) H1-antihistamine of the ethanolamine chemical group, sold as the succinate salt. First-generation H1-antihistamines act at histamine H1-receptors and cross readily into the brain, which is why they cause drowsiness. In the United States it is sold over the counter as a 25 mg night-time sleep aid and as a component of night-time cold and flu products, and on prescription at 10 mg combined with 10 mg pyridoxine hydrochloride in a delayed-release tablet for nausea and vomiting of pregnancy. The same molecule combined with pyridoxine and dicyclomine was marketed as Bendectin until production was discontinued in 1983.

What the research says

The evidence is mixed and use-specific. For nausea and vomiting of pregnancy the single pivotal placebo-controlled trial found a statistically significant but small difference on a 13-point symptom scale, and an independent reanalysis of the same trial's individual data concluded there was no clinically important benefit; a Cochrane review of early-pregnancy interventions called the supporting evidence limited. Its fetal safety is the best-studied part of the record, and a meta-analysis of 27 Bendectin studies found no increase in malformations. For sleep, the evidence is preliminary and conflicting, with no long-term placebo-controlled data; for the common cold, antihistamine monotherapy has no clinically significant effect. Harms are well documented: somnolence, next-day impairment of driving, delirium and falls in older adults, an association between cumulative anticholinergic exposure and dementia, dependence on escalating doses, and rhabdomyolysis with acute renal failure in overdose.

Evidence grade: Disputed.

How it works

Drug class: First-generation (sedating) H1-antihistamine of the ethanolamine group, with anticholinergic properties

Doxylamine blocks histamine H1-receptors. H1-antihistamines are now understood to work as inverse agonists at these receptors rather than as simple blockers, and first-generation drugs like doxylamine pass easily into the brain, which produces the drowsiness, impaired concentration and dry mouth that come with them. The FDA label for the pregnancy combination states plainly that how the combination works for nausea is not known. (Source 1)

What it is used for

• One placebo-controlled trial of 256 analysed women found a 0.7-point advantage on a 13-point emesis score, which the FDA accepted; an independent reanalysis of the same patient-level data found the difference was not statistically significant under other handling of missing data and fell well short of the 3-point difference the trial itself had prespecified as clinically important. A Cochrane review found only limited trial evidence for it. Evidence: disputed. (Source 2)
• The American Academy of Sleep Medicine's review of non-prescription insomnia treatments described the evidence for first-generation H1-antihistamines as preliminary and conflicting for short-term use only. The one randomised doxylamine insomnia trial we could reach compared two doxylamine brands with no placebo arm. No placebo-controlled trial beyond a few nights was found. Evidence: limited. (Source 3)
• Cochrane found antihistamine monotherapy has at most a short-lived effect on overall cold symptom severity on days one and two and no clinically significant effect on nasal obstruction, runny nose or sneezing, and no evidence of effectiveness in children. Antihistamine-decongestant combinations do show a global benefit in adults but with more adverse effects. Evidence: limited. (Source 4)
• Doxylamine is sold over the counter as an antihistamine for allergy symptoms, but we found no randomised placebo-controlled outcome trial of doxylamine alone for allergic rhinitis in the literature we searched. Professional bodies now advise second-generation antihistamines instead because of the harms of the first-generation drugs. Evidence: unknown. (Source 5)
• No trial we found tested doxylamine beyond a few weeks. A randomised crossover trial in chronic urticaria showed that adding a sedating first-generation antihistamine at night increased daytime sleepiness without improving the condition, and a published case describes escalation from 25 mg to 125 mg daily over years. Evidence: not-supported. (Source 6)

Interactions

• Monoamine oxidase inhibitors (label): MAO inhibitors intensify and prolong the central nervous system and drying effects of doxylamine. The prescription combination is contraindicated in anyone taking them. (Source 7)
• Alcohol (label): Alcohol adds to the drowsiness. The prescription label advises against combining them and says the combination can cause severe drowsiness leading to falls or accidents; the over-the-counter sleep aid label says to avoid alcoholic drinks. Limit: The label is a position, not a measurement. The nearest human experiment is the Iowa driving simulator trial, which measured diphenhydramine and alcohol separately rather than together. (Source 7)
• Alcohol, measured against driving performance (clinical trial): In a randomised simulator trial a sedating antihistamine impaired driving more than alcohol at about the legal limit did, and participants could not tell from how drowsy they felt that they were impaired. Limit: Diphenhydramine, not doxylamine, and the two were given in separate periods rather than together, so this measures comparable, not combined, impairment. (Source 8)
• Other sedating drugs: hypnotics, tranquillisers, opioids and other antihistamines (label): Added sedation. The prescription label's counselling section names alcohol, other antihistamines in cough and cold medicines, opiates and sleep aids as combinations to avoid because somnolence could worsen leading to falls or accidents. (Source 9)
• Other anticholinergic medicines (clinical trial): Doxylamine adds to total anticholinergic burden, which is associated in cohort studies with falls and fall-related injuries and with incident dementia. Limit: The design is a retrospective cohort, not a trial; the evidence type closest on the allowed list is an observational study. The scale rates drugs by burden level rather than naming doxylamine. (Source 10)
• Food, for the delayed-release pregnancy tablet (pharmacokinetic study): Taking the delayed-release tablet with food may further delay its onset and reduce how much is absorbed, so the label directs taking it on an empty stomach with water. (Source 7)
• Food, for the plain 25 mg tablet (pharmacokinetic study): For the plain immediate-release tablet, a high-fat high-calorie meal made no measurable difference to peak concentration or total exposure. (Source 11)
• CYP2D6 inhibitors and poor CYP2D6 metaboliser status (pharmacokinetic study): Anticholinergic drugs are cleared partly by CYP enzymes, and a review of this literature reports that poor CYP2D6 metabolisers reach higher drug exposures, as do older adults and especially older women. Limit: This is a narrative review of anticholinergic drugs as a group. It does not report CYP2D6 data for doxylamine itself, and we found no doxylamine-specific CYP phenotype study. (Source 12)
• Sedating supplements: valerian, melatonin, kava, St John's wort (theoretical): We found no human study of doxylamine combined with any sedating supplement. The reason to be cautious is additive sedation: the American Academy of Sleep Medicine's review of non-prescription insomnia treatments assessed valerian and first-generation antihistamines side by side as mild hypnotics, and separately flagged real risks from kava kava. Any interaction is therefore inferred, not measured. Limit: No pharmacokinetic or clinical interaction study exists in what we searched. Treat this as a theoretical additive-sedation concern only. (Source 3)
• Urine drug screening for methadone, opiates and phencyclidine (label): Doxylamine can produce false positive immunoassay results for methadone, opiates and PCP, which need confirmation by a method such as gas chromatography mass spectrometry. (Source 7)

Stopping it

• The prescription combination is meant to be taken daily rather than as needed, and the label directs the prescriber to reassess whether it is still needed as pregnancy goes on. It gives no taper. (Source 13)
• The over-the-counter sleep aid label sets a two-week ceiling on continuous use and tells people whose sleeplessness persists past that to see a doctor, because insomnia can be a symptom of something else. There is no tapering instruction. (Source 14)
• A 2026 scoping review of rebound itching and hives after stopping long-term antihistamines found reports only for cetirizine and levocetirizine. No report involving doxylamine was found, so a doxylamine rebound syndrome is neither established nor ruled out. (Source 15)
• The same review notes that whether stopping other antihistamines can cause rebound itching is still an open research question, and that among the strategies reported, tapering worked least often. (Source 16)
• Dependence on doxylamine is documented, though only in case reports. One describes a man who went from 25 mg to 125 mg a day over years of uninterrupted use for insomnia and then needed treatment to stop. (Source 17)

What goes wrong

In the pivotal trial's adverse reaction table, somnolence was the only reaction reaching 5% and exceeding placebo, at 14.3% versus 11.7%. (Source 18)

• Official position, Moderate certainty.
• Size: 261 women (133 active, 128 placebo)
• Who: Women with nausea and vomiting of pregnancy, mean gestational age 9.3 weeks.
• How long: 15 days.
• Result: Somnolence 19 of 133 (14.3%) on doxylamine-pyridoxine versus 15 of 128 (11.7%) on placebo.
• Funding: Regulatory record of a manufacturer-sponsored trial.

Limit of this finding: The table shows only reactions at 5% or more AND more common than placebo, so it is not a full adverse event list; the Postmarketing Experience section in the same reference lists urinary retention, disorientation, nightmares, palpitation and tachycardia without rates. The label’s own HTML table runs the two column headings together, so this row was rebuilt cell by cell from the SPL XML: the 133 is the doxylamine-pyridoxine arm and the 128 is placebo.

Somnolence: Doxylamine Succinate and Pyridoxine Hydrochloride (N = 133) 19 (14.3%), Placebo (n = 128) 15 (11.7%)

The label warns that doxylamine-pyridoxine causes somnolence and that combining it with alcohol or other CNS depressants can cause severe drowsiness leading to falls or accidents. (Source 9)

• Official position, Certainty not rated.
• Size: Not applicable.
• Who: Women taking the prescription combination.
• How long: Not applicable.
• Result: No rate given for falls or accidents.
• Funding: Regulatory position, label effective 2026-08-24.

Doxylamine succinate and pyridoxine hydrochloride may cause somnolence due to the anticholinergic properties of doxylamine succinate, an antihistamine.

In a driving-simulator trial, a sedating antihistamine impaired driving more than alcohol at roughly the legal limit. (Source 19)

• Randomized trial, Moderate certainty.
• Size: 40 licensed drivers.
• Who: Licensed drivers aged 25 to 44 with seasonal allergic rhinitis.
• How long: Four single-dose treatment periods a week apart, 1 hour of driving each.
• Result: Lane keeping impaired after diphenhydramine 50 mg and after alcohol (about 0.1% blood alcohol) compared with fexofenadine; overall driving performance poorest after diphenhydramine; self-reported drowsiness did not predict impairment.
• Funding: Indexed as Research Support, Non-U.S. Gov't and Research Support, U.S. Gov't, P.H.S.; this trial of a competitor's non-sedating drug carries an obvious commercial interest, which the abstract does not disclose.

Limit of this finding: The drug tested was diphenhydramine, not doxylamine. This is class evidence for sedating first-generation antihistamines, not a measurement of doxylamine.

After participants took diphenhydramine, driving performance was poorest, indicating that diphenhydramine had a greater impact on driving than alcohol did.

Drivers could not tell from how drowsy they felt whether they were impaired. (Source 8)

• Randomized trial, Moderate certainty.
• Size: 40 licensed drivers.
• Who: Licensed drivers with seasonal allergic rhinitis.
• How long: Single doses, four periods.
• Result: Self-reported drowsiness did not predict lack of coherence and was only weakly associated with following distance, steering instability and left-lane excursion.
• Funding: See the preceding finding.

Limit of this finding: Tested with diphenhydramine. The source prints "leftlane" as one word; quoted as printed.

Self-reported drowsiness did not predict lack of coherence and was weakly associated with minimum following distance, steering instability, and leftlane excursion.

Cumulative exposure to strongly anticholinergic drugs is associated with a higher later risk of dementia in a nested case-control study of 284,343 people. (Source 20)

• Case-control study, Low certainty.
• Size: 58,769 dementia cases and 225,574 matched controls.
• Who: English primary care patients aged 55 and over in the QResearch database.
• How long: Exposure measured 1 to 11 years before diagnosis, with 3-13 and 5-20 year windows also tested.
• Result: Adjusted odds ratio rose from 1.06 (95% CI 1.03-1.09) at 1-90 total standardised daily doses to 1.49 (95% CI 1.44-1.54) above 1,095 TSDDs; population-attributable fraction 10.3%.
• Funding: Not stated in the abstract.

Limit of this finding: This is an observational association across 56 anticholinergic drugs, not a causal finding and not specific to doxylamine; the significant drug-class results reported were for antidepressants, antiparkinson drugs, antipsychotics, bladder antimuscarinics and antiepileptics. Prescription records also miss over-the-counter doxylamine entirely.

The adjusted OR for dementia increased from 1.06 (95% CI, 1.03-1.09) in the lowest overall anticholinergic exposure category (total exposure of 1-90 TSDDs) to 1.49 (95% CI, 1.44-1.54) in the highest category (>1095 TSDDs), compared with no anticholinergic drug prescriptions in the 1 to 11 years before the index date.

In a prospective cohort, higher cumulative anticholinergic use was associated with incident dementia, and first-generation antihistamines were one of the three most-used classes. (Source 21)

• Cohort study, Low certainty.
• Size: 3,434 participants without dementia at entry; 797 (23.2%) developed dementia.
• Who: Adults 65 and over in the Adult Changes in Thought study, Seattle.
• How long: Mean 7.3 years of follow-up, exposure over the preceding 10 years.
• Result: Adjusted hazard ratio for dementia 1.54 (95% CI 1.21-1.96) above 1,095 TSDDs versus non-use; 0.92 (0.74-1.16), 1.19 (0.94-1.51) and 1.23 (0.94-1.62) in the lower exposure bands; test for trend P < .001.
• Funding: Research Support, N.I.H., Extramural and Research Support, Non-U.S. Gov't.

Limit of this finding: Observational, and about anticholinergic drugs as a group: doxylamine itself is not named anywhere in the study. Exposure came from pharmacy dispensing data, which does not capture over-the-counter purchases, and over-the-counter doxylamine is bought that way. Only the highest exposure band reached statistical significance.

The most common anticholinergic classes used were tricyclic antidepressants, first-generation antihistamines, and bladder antimuscarinics.

Older inpatients cared for by physicians who prescribe first-generation antihistamines more often had higher odds of in-hospital delirium. (Source 22)

• Survey study, Low certainty.
• Size: 328,140 admissions to 755 physicians.
• Who: General medicine inpatients aged 65 and over at 17 Ontario hospitals, 2015-2022.
• How long: Admissions between 1 April 2015 and 31 March 2022.
• Result: Delirium in 32.3% of admissions in the lowest-prescribing quartile versus 36.6% in the highest; adjusted OR 1.08 (95% CI 1.05-1.10) per 1% absolute increase in prescribing, and 1.41 (95% CI 1.28-1.56) highest versus lowest quartile.
• Funding: Research Support, Non-U.S. Gov't.

Limit of this finding: Cross-sectional and based on physician prescribing rates rather than individual exposure, and delirium was identified by a machine learning tool; this is an association, not proof that the antihistamine caused the delirium. The drug mix is not broken down by agent and doxylamine is not named. One sentence elsewhere in the same Results section also mislabels a percentage of admissions as a percentage of physicians, so read the source’s quartile sentences carefully.

In adjusted analyses, every 1% absolute increase in first-generation antihistamine prescribing was associated with 8% increased odds of delirium (aOR: 1.08, 95% CI: 1.05-1.10).

Anticholinergic drug burden is associated with falls and fall-related injuries in older adults with impaired cognition. (Source 10)

• Cohort study, Low certainty.
• Size: 10,698 adults; 2,015 (18.8%) had a fall or fall-related injury.
• Who: Adults 65 and over with mild cognitive impairment or dementia plus two or more chronic conditions in a US integrated delivery system.
• How long: Median follow-up 366 days.
• Result: At a daily anticholinergic cognitive burden score of 5, combining level 2 and level 3 drugs carried HR 2.06 (95% CI 1.51-2.83); multiple level 1 drugs together HR 1.16 (95% CI 1.03-1.32)
• Funding: Research Support, N.I.H., Extramural and Research Support, Non-U.S. Gov't.

Limit of this finding: Retrospective and not specific to doxylamine; it quantifies burden scores, not individual drugs.

Among patients with a daily ACB score of 5, the greatest increase in risk of falls or fall-related injuries was seen when level 2 and level 3 drugs were used in combination [hazard ratio (HR) 2.06; 95% confidence interval (CI) 1.51-2.83].

Rhabdomyolysis is common after doxylamine overdose and is predicted by the amount ingested. (Source 23)

• Case series, Low certainty.
• Size: 27 patients.
• Who: Patients admitted to a Korean university teaching hospital for doxylamine overdose, July 2000 to September 2005.
• How long: Index admission.
• Result: 16 of 27 (59%) developed rhabdomyolysis; 3 of those 16 (19%) developed acute renal failure. Ingestion of 20 mg/kg or more predicted rhabdomyolysis with sensitivity 81%, specificity 82%, positive predictive value 87%, negative predictive value 75%.
• Funding: Research Support, Non-U.S. Gov't.

Limit of this finding: Three things in the source to hold in mind. Its conclusion says rhabdomyolysis occurred "in 87% of patients who ingested more than 20 mg/kg", but 87 per cent is the positive predictive value reported in the same abstract, not an incidence, so the 87 per cent must not be read as a rate. The same abstract switches between "at or above 20 mg/kg" and "more than 20 mg/kg" for the same threshold. And it prints "creatitnine" for creatinine. None of this has been corrected; the quoted incidence here is the series’ own 16 of 27.

Sixteen (59%) of 27 patients developed rhabdomyolysis and three (19%) of 16 patients with rhabdomyolysis also developed acute renal failure.

In a larger series, 21% of doxylamine overdose patients with normal initial creatine phosphokinase went on to develop rhabdomyolysis. (Source 24)

• Case series, Low certainty.
• Size: 169 patients.
• Who: Emergency department presentations after doxylamine overdose at a tertiary Korean teaching hospital, 1998-2009.
• How long: Index presentation and laboratory follow-up.
• Result: 35 of 169 (21%) developed rhabdomyolysis; independent predictors were the amount ingested (P = .004) and heart rate (P < .001)
• Funding: Not stated in the abstract.

Thirty-five (21%) of the 169 patients developed rhabdomyolysis.

A case report documents severe rhabdomyolysis with acute liver and kidney failure needing haemodialysis after an overdose of 30 doxylamine tablets. (Source 25)

• Case report, Very low certainty.
• Size: 1 patient.
• Who: 52-year-old man.
• How long: Single overdose, intensive care admission.
• Result: Raised creatine kinase, urea, creatinine, troponins, transaminases and phosphate; severe rhabdomyolysis, acute liver failure and acute kidney injury.
• Funding: Not stated.

Limit of this finding: A single case, n=1, and the abstract gives no creatine kinase, creatinine or doxylamine level and no tablet strength, so no dose in mg can be read from it. The same abstract also summarises other papers, with hedges such as "Studies describe" and "One study explained"; those mechanistic statements belong to the cited literature, not to this case. It prints "creatinine kinase" for creatine kinase; quoted as printed.

The patient was admitted to the medical intensive care unit for severe rhabdomyolysis, acute liver failure, and acute kidney injury secondary to doxylamine intoxication.

The label records fatalities from doxylamine overdose in children, with coma, grand mal seizures and cardiorespiratory arrest. (Source 26)

• Official position, Certainty not rated.
• Size: Not quantified.
• Who: Children.
• How long: Not applicable.
• Result: A toxic dose in children above 1.8 mg/kg has been reported; a 3-year-old died 18 hours after ingesting 1,000 mg; no correlation between amount ingested, plasma level and symptoms.
• Funding: Regulatory position, label effective 2026-08-24.

Fatalities have been reported from doxylamine overdose in children. The overdose cases have been characterized by coma, grand mal seizures and cardiorespiratory arrest.

At toxic doses the label states doxylamine causes seizures, rhabdomyolysis, acute renal failure and death. (Source 26)

• Official position, Certainty not rated.
• Size: Not quantified.
• Who: Anyone taking a toxic dose.
• How long: Not applicable.
• Result: No rates given; the label notes a delayed-release formulation may delay the appearance of intoxication.
• Funding: Regulatory position, label effective 2026-08-24.

At toxic doses, doxylamine exhibits anticholinergic effects, including seizures, rhabdomyolysis, acute renal failure and death.

A case report documents dose escalation and dependence on over-the-counter doxylamine over five years of uninterrupted use. (Source 17)

• Case report, Very low certainty.
• Size: 1 patient.
• Who: 43-year-old man who began taking doxylamine for insomnia.
• How long: 5 years of uninterrupted use, the last 3 at the highest dose.
• Result: Escalation from 25 mg daily to 125 mg daily.
• Funding: Not stated.

Limit of this finding: A single case. The same report notes there are few studies of doxylamine dependence, so the frequency of this is unknown.

who started using over-the-counter doxylamine succinate at 25 mg/day due to insomnia, gradually increased to 125 mg/day for the last 3 years continuing his doxylamine succinate intake for 5 years uninterrupted

A systematic review of over-the-counter medicine misuse found antihistamines among the drugs that can induce psychotic symptoms when abused. (Source 27)

• Systematic review, Very low certainty.
• Size: 46 studies from an initial 2,677 articles.
• Who: People misusing over-the-counter antihistamines, cough medicines and decongestants.
• How long: Varied; mostly case material.
• Result: Paranoia, hallucinations and thought disorders reported; dextromethorphan associated with chronic psychosis, other agents more often with acute substance-induced psychosis.
• Funding: Not stated in the abstract; PROSPERO CRD42024527558.

Limit of this finding: The review's stated search terms were diphenhydramine, promethazine, chlorpheniramine and dimenhydrinate; doxylamine was not among them, so this is class evidence.

Key findings indicate that antihistamines, dextromethorphan, and other OTC drugs can induce psychotic symptoms, such as paranoia, hallucinations, and thought disorders when abused.

A Cochrane review found that more people on antihistamine-decongestant cold combinations reported an adverse effect than on control, 128 of 419 against 100 of 423, but its own odds ratio for that difference was not statistically significant. (Source 28)

• Systematic review, Moderate certainty.
• Size: 842 participants across the adverse-effect analysis (419 active, 423 control) within 14 antihistamine-decongestant trials.
• Who: Children and adults with the common cold.
• How long: 3 to 10 days.
• Result: 128/419 versus 100/423 participants suffered one or more adverse effects, odds ratio 1.58 (95% CI 0.78 to 3.21), moderate certainty of evidence.
• Funding: Cochrane review; indexed as Research Support, Non-U.S. Gov't.

Limit of this finding: Two problems in the review’s own text, quoted as printed and not corrected. First, it prints the control figure as "100/423 (13%)", but 100 of 423 is 23.6 per cent, so the printed percentage contradicts its own fraction; read the fractions, not the percentages. Second, it says the group "experienced more adverse effects" while the odds ratio it gives, 1.58 with a 95% confidence interval of 0.78 to 3.21, includes 1, which means the difference was not statistically significant. The pooled trials used various antihistamines, not doxylamine.

Adverse effects: the antihistamine-decongestant group experienced more adverse effects than the control group: 128/419 (31%) versus 100/423 (13%) participants suffered one or more adverse effects (OR 1.58, 95%CI 0.78 to 3.21; moderate certainty of evidence).

A Canadian allergy society position holds that first-generation antihistamines have an unfavourable risk-benefit profile and should not be first-line. (Source 5)

• Official position, Certainty not rated.
• Size: Not applicable.
• Who: People with allergic rhinitis and chronic urticaria.
• How long: Not applicable.
• Result: No rates given; the statement lists sedation, impaired cognition, poor sleep quality, dry mouth, dizziness and orthostatic hypotension as significant and common, and reports deaths from accidents, overdoses and sudden cardiac death.
• Funding: Canadian Society of Allergy and Clinical Immunology position statement, 2019.

Limit of this finding: A professional body's position dated 2019, not a measurement. It names diphenhydramine and hydroxyzine as its examples, not doxylamine.

Older, first-generation AHs (e.g. diphenhydramine, hydroxyzine) have significant and common side effects including sedation, impairment with decreased cognitive function, poor sleep quality, dry mouth, dizziness, and orthostatic hypotension.

The FDA does not recommend antihistamine-containing cough and cold products in children under 2, and safety and efficacy data under 6 are lacking. (Source 29)

• Official position, Certainty not rated.
• Size: Not applicable.
• Who: Children under 6 years.
• How long: Not applicable.
• Result: No rates given; the review notes serious adverse effects including death, especially with incorrect use.
• Funding: Review article; funding not stated.

Limit of this finding: This is a narrative review restating a regulatory position; it does not quantify the risk.

Currently, the US Food and Drug Administration (FDA) does not recommend the use of cough and cold products that contain an antihistamine or decongestant in children younger than 2 years.

What the evidence supports

In the pivotal placebo-controlled trial, delayed-release doxylamine-pyridoxine improved nausea and vomiting of pregnancy scores significantly more than placebo, but the difference was under one point on a 13-point scale. (Source 2)

• Randomized trial, Moderate certainty.
• Size: 256 women analysed (131 active, 125 placebo) of 261 randomised.
• Who: Pregnant women 7 to 14 weeks gestation with nausea and vomiting of pregnancy, 6 US outpatient obstetric practices.
• How long: 14 days.
• Result: PUQE score change -4.8 ± 2.7 with Diclectin vs -3.9 ± 2.6 with placebo; P = .006. 48.9% of Diclectin women vs 32.8% of placebo women asked to continue the drug compassionately (P = .009)
• Funding: Supported by the manufacturer (Duchesnay) and conducted with US NIH network investigators; the paper is indexed as Research Support, Non-U.S. Gov't.

Limit of this finding: The authors' conclusion calls the drug effective; the size of the difference is what is disputed, not its direction. Treatment allocation and n are in the trial's Study Design section (koren-2010-dic301-design).

Diclectin use resulted in a significantly larger improvement in symptoms of nausea and vomiting of pregnancy compared with placebo based on both the pregnancy unique quantification of emesis score (-4.8 ± 2.7 vs -3.9 ± 2.6; P = .006) and quality of life.

The FDA label reports the same trial result as a 0.7-point mean difference on the PUQE scale. (Source 30)

• Official position, Moderate certainty.
• Size: 261 women randomised.
• Who: Adult women 18 years or older, 7 to 14 weeks gestation.
• How long: 15 days.
• Result: 0.7-point mean decrease from baseline in PUQE score at Day 15 vs placebo (95% CI 0.2 to 1.2, p = 0.006), intent-to-treat with last observation carried forward.
• Funding: Regulatory position; the trial was sponsored by the manufacturer.

Limit of this finding: This is the FDA’s position as recorded in the label effective 2026-08-24, not independent evidence. The analysis uses last observation carried forward, the imputation method the independent reanalysis found to be decisive. Table 6 in the label’s own HTML is malformed, so it was rebuilt from the SPL XML: the Day-15 change was -4.8 ± 2.7 on doxylamine-pyridoxine and -3.9 ± 2.6 on placebo, and -0.7 [-1.2, -0.2] is the treatment difference, not a placebo value.

There was a 0.7 (95% confidence interval 0.2 to 1.2 with p-value 0.006) mean decrease (improvement in nausea and vomiting symptoms) from baseline in PUQE score at Day 15 with doxylamine succinate and pyridoxine hydrochloride compared to placebo

A meta-analysis of 27 epidemiological studies found no increase in birth defects after first-trimester Bendectin exposure. (Source 31)

• Meta-analysis, Moderate certainty.
• Size: 16 cohort and 11 case-control studies.
• Who: Pregnancies exposed to Bendectin (doxylamine, dicyclomine, pyridoxine) in the first trimester.
• How long: Studies published 1963 to 1991.
• Result: Pooled relative risk of any malformation at birth 0.95 (95% CI 0.88 to 1.04); category-specific pooled estimates ranged from 0.81 for oral clefts to 1.11 for limb reductions, all confidence intervals including 1.
• Funding: Not stated in the abstract.

Limit of this finding: The source prints "95% Cl" with a lower-case L instead of "95% CI"; we have quoted it as printed. Bendectin contained dicyclomine as well as doxylamine and pyridoxine, so this is not an estimate for doxylamine alone.

The pooled estimate of the relative risk of any malformation at birth in association with exposure to Bendectin in the first trimester was 0.95 (95% Cl 0.88 to 1.04).

A high-fat meal did not change the pharmacokinetics of the plain 25 mg doxylamine tablet. (Source 32)

• Blood level study, Low certainty.
• Size: 24 healthy volunteers (12 male, 12 female)
• Who: Healthy adult volunteers.
• How long: Two single-dose periods 7 days apart, plasma sampled to 60 hours.
• Result: Fasting mean Cmax 118.21 ng/mL and AUC(t) 1746.97 ng·h/mL; fed mean Cmax 120.99 ng/mL and AUC(t) 1712.20 ng·h/mL; fed:fasting geometric mean ratios with 90% confidence intervals within 80-125%.
• Funding: Not stated in the abstract; the paper is a formulation bioavailability study.

Limit of this finding: This is the plain immediate-release 25 mg tablet. The FDA label for the delayed-release pregnancy combination says the opposite for that formulation, that food delays onset and may reduce absorption. The two are not in conflict because the formulations differ, but the distinction matters.

High-fat, high-calorie food intake does not affect the kinetics of doxylamine in healthy subjects.

What the evidence does not support

An independent reanalysis of the same trial's patient-level data found the advantage over placebo was not statistically significant when missing data were handled differently. (Source 33)

• Randomized trial, Moderate certainty.
• Size: 140 randomised per group; 131 active and 125 control analysed; 101 and 86 provided final-day outcomes.
• Who: Pregnant women 7 to 14 weeks gestation with moderate nausea and vomiting of pregnancy.
• How long: 14 days.
• Result: 0.73 points (95% CI 0.21 to 1.25) with last observation carried forward; 0.38 (95% CI -0.08 to 0.84) using complete data.
• Funding: Reanalysis used the clinical study report obtained from Health Canada; indexed as Research Support, Non-U.S. Gov't.

There was greater improvement in symptoms scores with doxylamine-pyridoxine compared with placebo (0.73 points; 95% CI 0.21 to 1.25) when last observation carried forward imputation was used for missing data but the difference is not statistically significant using other approaches to missing data (e.g. 0.38; 95% CI -0.08 to 0.84 using complete data).

The reanalysis concluded the difference falls short of the 3-point difference the trial itself had prespecified as the minimum clinically important one. (Source 34)

• Randomized trial, Moderate certainty.
• Size: 256 analysed.
• Who: Pregnant women with moderate nausea and vomiting of pregnancy.
• How long: 14 days.
• Result: Magnitude below the prespecified minimal clinically important difference of 3 points on the 13-point PUQE scale.
• Funding: Independent reanalysis of a manufacturer-sponsored trial.

There is a trend towards efficacy for nausea and vomiting symptoms with doxylamine-pyridoxine compared with placebo but the statistical significance of the difference depends on the method of handling missing data and the magnitude of the difference suggests that there is no clinically important benefit employing the prespecified minimal clinically important difference or "expected difference" of 3 points.

The authors of the restored 8-way Bendectin trial concluded it should not be used to support efficacy. (Source 35)

• Randomized trial, Very low certainty.
• Size: 1,599 analysed of 2,308 randomised.
• Who: Patients in the first 12 weeks of pregnancy with nausea or vomiting.
• How long: 7 nights.
• Result: No usable efficacy estimate; high risk of bias.
• Funding: RIAT restoration of an unpublished industry trial.

it should not be used to support the efficacy of doxylamine, pyridoxine or dicyclomine for the treatment of nausea and vomiting during pregnancy because of a high risk of bias.

A Cochrane review of interventions for nausea and vomiting in early pregnancy found only limited trial evidence supporting doxylamine-pyridoxine. (Source 36)

• Systematic review, Low certainty.
• Size: 41 trials, 5,449 women.
• Who: Women up to 20 weeks' gestation with nausea, vomiting or retching; hyperemesis gravidarum excluded.
• How long: Varied by trial.
• Result: No pooled estimate was possible for most outcomes because of heterogeneity; the review reports only limited evidence for pharmacological agents including doxylamine-pyridoxine.
• Funding: Indexed as Research Support, Non-U.S. Gov't.

Limit of this finding: The review's own text misspells the drug as "Doxylamine-pyridoxoine"; we have quoted it as printed rather than correcting it.

There was only limited evidence from trials to support the use of pharmacological agents including vitamin B6, Doxylamine-pyridoxoine and other anti-emetic drugs to relieve mild or moderate nausea and vomiting.

Cochrane's overall verdict on early-pregnancy nausea treatment was that no particular intervention is supported by high-quality evidence. (Source 37)

• Systematic review, Low certainty.
• Size: 41 trials, 5,449 women.
• Who: Women in early pregnancy with nausea and vomiting.
• How long: Varied.
• Result: No intervention supported by high-quality evidence; the review notes this is not the same as the interventions being ineffective.
• Funding: Indexed as Research Support, Non-U.S. Gov't.

There is a lack of high-quality evidence to support any particular intervention. This is not the same as saying that the interventions studied are ineffective, but that there is insufficient strong evidence for any one intervention.

In a small head-to-head randomised trial, ondansetron relieved pregnancy nausea better than doxylamine with pyridoxine. (Source 38)

• Randomized trial, Low certainty.
• Size: 36 women randomised (18 per arm); 13 and 17 completed follow-up.
• Who: Women with nausea and vomiting of pregnancy.
• How long: 5 days.
• Result: Median 100-mm VAS nausea score fell 51 mm (IQR 37-64) with ondansetron vs 20 mm (IQR 8-51) with pyridoxine plus doxylamine, P = .019; vomiting VAS fell 41 vs 17, P = .049.
• Funding: Not stated in the abstract.

Limit of this finding: Only 36 women were randomised and follow-up was incomplete: the printed "13 (72%)" and "17 (94%)" are of 18 per arm, so the comparison rests on 30 women, not 36. The Results section alone does not say that plainly. A single small trial cannot settle the comparison.

Patients randomized to ondansetron were more likely to have an improvement in their baseline nausea as compared with those using pyridoxine and doxylamine over the course of 5 days of treatment (median VAS score decreased 51 mm [interquartile range 37-64] compared with 20 mm [8-51]; P=.019).

A national birth cohort found no association between doxylamine or other antiemetic exposure in pregnancy and childhood neurodevelopmental disorders. (Source 39)

• Cohort study, Low certainty.
• Size: 630,904 children; 1,383 (0.2%) exposed to doxylamine.
• Who: Mother-child pairs in South Korea's National Health Insurance Service database, 2009-2023.
• How long: Children followed to diagnosis of any of seven neurodevelopmental disorders.
• Result: No substantial association for antiemetic exposure overall; the only elevated signal was metoclopramide and ADHD (HR 1.12, 95% CI 1.06-1.18)
• Funding: Not stated in the abstract.

Limit of this finding: Only 1,383 children (0.2% of the cohort) were exposed to doxylamine, so the doxylamine-specific estimates are imprecise; the primary exposure of this study was metoclopramide.

There was no substantial association between antiemetic exposure during pregnancy and neurodevelopmental disorders and delays.

A dedicated randomised safety trial found no excess of adverse events with doxylamine-pyridoxine over placebo in pregnancy. (Source 40)

• Randomized trial, Low certainty.
• Size: 256 women (131 active, 125 placebo)
• Who: Pregnant women with nausea and vomiting of pregnancy.
• How long: 14 days at 2 to 4 tablets daily.
• Result: No increased rate of any adverse event over placebo, including CNS depression and gastrointestinal or cardiovascular events.
• Funding: Indexed as Research Support, Non-U.S. Gov't; the trial was manufacturer-sponsored.

Limit of this finding: This is a secondary safety report from the same 256-woman, 14-day trial as the efficacy result, and the label's own table shows somnolence was more common on drug than placebo (14.3% vs 11.7%). A 14-day trial in 256 women cannot rule out uncommon harms.

Doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg use was not associated with an increased rate of any adverse event over placebo, including CNS depression, gastrointestinal or cardiovascular involvement.

Adding a sedating first-generation antihistamine at night increased daytime sleepiness without improving the condition being treated. (Source 6)

• Randomized trial, Low certainty.
• Size: 24 patients.
• Who: Adults with difficult-to-treat chronic spontaneous urticaria.
• How long: Two 5-day crossover periods.
• Result: Both regimens reduced urticaria activity and night-time sleep disturbance equally (P < 0.001, no significant difference between them); daytime somnolence fell with levocetirizine alone (P = 0.006) but not with levocetirizine plus hydroxyzine (P = 0.218), and direct comparison favoured monotherapy (P = 0.026)
• Funding: Research Support, Non-U.S. Gov't.

Limit of this finding: The sedating drug was hydroxyzine, not doxylamine, and only 24 patients took part. The quote uses middle dots for decimal points, as the journal prints them.

Compared with baseline, daytime somnolence was significantly reduced by levocetirizine monotherapy (P = 0·006) but not by levocetirizine plus hydroxyzine (P = 0·218).

The belief that a sedating antihistamine at night helps sleep was not supported by the trial that tested it. (Source 41)

• Randomized trial, Low certainty.
• Size: 24 patients.
• Who: Adults with chronic spontaneous urticaria.
• How long: Two 5-day crossover periods.
• Result: No added benefit from the night-time sedating antihistamine.
• Funding: Research Support, Non-U.S. Gov't.

Limit of this finding: The drug actually tested was hydroxyzine, not doxylamine, in 24 patients with chronic urticaria over a short crossover. This is class evidence about sedating first-generation antihistamines at night, not a measurement of doxylamine.

The widespread belief that sleep is aided by the addition of a sedating first-generation H1 -antihistamine, usually hydroxyzine, at night is not supported.

The American Academy of Sleep Medicine's review found the evidence that first-generation antihistamines work as hypnotics is preliminary and conflicting, and limited to short-term use. (Source 3)

• Expert review, not systematic, Very low certainty.
• Size: Not stated; PubMed search of English-language articles 1980 to 2002 plus reference lists.
• Who: Adults with insomnia symptoms; paediatric literature excluded.
• How long: Short-term use only.
• Result: No pooled estimate; the review reports preliminary but conflicting evidence.
• Funding: Produced by the AASM Clinical Practice Review Committee.

Limit of this finding: The search ran only to October 2002 and no method was stated beyond the search terms, so this is a dated expert summary, not a systematic review. It addresses the class, not doxylamine by name.

There is preliminary but conflicting evidence suggesting Valerian officinalis L. and first-generation histamine-1-receptor antagonists have efficacy as mild hypnotics over short-term use.

Antihistamine monotherapy for the common cold has at most a brief effect on overall symptom severity and none on the individual symptoms. (Source 4)

• Systematic review, Moderate certainty.
• Size: 18 randomised trials, 4,342 participants (212 children)
• Who: People with naturally occurring or experimentally induced common cold, without an allergic component.
• How long: Up to 10 days.
• Result: Day 1 or 2 benefit in 45% on antihistamine versus 38% on placebo (OR 0.74, 95% CI 0.60 to 0.92); no difference at 3-4 days or 6-10 days; rhinorrhoea day 3 mean difference -0.23 (95% CI -0.39 to -0.06) and sneezing day 3 -0.35 (95% CI -0.49 to -0.20), both judged clinically non-significant.
• Funding: Cochrane review; funding not stated in the abstract.

Limit of this finding: The review states the day one or two result as "45% had a beneficial effect with antihistamines versus 38% with placebo (odds ratio (OR) 0.74, 95% confidence interval (CI) 0.60 to 0.92)". Those two percentages give an odds ratio of about 1.34 in favour of antihistamines, so the 0.74 the review prints is the odds ratio for the opposite outcome, having no benefit. Read as printed it looks as though antihistamines did worse, and it should not be read that way: the percentages are the right way round and the figure is a small short-lived advantage on day one or two only. We have quoted the review as it stands and not altered the number. The review itself calls this effect clinically non-significant, and the pooled trials used various antihistamines rather than doxylamine.

However, there was no difference between antihistamines and placebo in the mid term (three to four days) to long term (six to 10 days).

Cochrane found no evidence that antihistamines are effective for colds in children. (Source 42)

• Systematic review, Low certainty.
• Size: Only 2 of 18 trials included children (212 children in total)
• Who: Children with the common cold.
• How long: Up to 10 days.
• Result: Conflicting results in the two paediatric trials; no demonstrated effectiveness.
• Funding: Cochrane review.

There is no evidence of effectiveness of antihistamines in children.

Cochrane found the effect of antihistamine-analgesic-decongestant cold combinations on individual symptoms probably too small to matter, with no evidence of benefit in young children. (Source 43)

• Systematic review, Low certainty.
• Size: 30 studies, 6,304 participants, 31 treatment comparisons.
• Who: Children and adults with the common cold.
• How long: Varied.
• Result: For antihistamine-analgesic-decongestant, pooled global effect 52% active versus 34% placebo, equivalent to under one point on a four- or five-point scale; OR of treatment failure 0.47 (95% CI 0.33 to 0.67, low certainty), NNTB 5.6 (95% CI 3.8 to 10.2)
• Funding: Cochrane review; indexed as Research Support, Non-U.S. Gov't.

Based on these scarce data, the effect on individual symptoms is probably too small to be clinically relevant.

Where the evidence is mixed

The never-published 1970s 8-way Bendectin trial reported that doxylamine alone and doxylamine with pyridoxine beat placebo on physician-rated improvement, but its authors judged it unusable. (Source 44)

• Randomized trial, Very low certainty.
• Size: 2,308 enrolled, data from 1,599 (69%) analysed, 14 US clinics.
• Who: Patients in the first 12 weeks of pregnancy with nausea or vomiting.
• How long: 7 nights.
• Result: "Evaluated moderate or excellent" in 57% on placebo; absolute differences versus placebo of 21 points (95% CI 11 to 30) for doxylamine/pyridoxine and 20 points (95% CI 10 to 29) for doxylamine alone.
• Funding: Restoration of an unpublished industry trial under the RIAT initiative; indexed as Research Support, Non-U.S. Gov't.

Limit of this finding: The same Results section states there is a high risk of bias from 31% attrition in a 7-day trial, no prespecified outcomes or analyses, and exclusion of data for questionable integrity. The abstract also lists "dicylomine/pyridoxine" and "dicyclomine/pyridoxine" as two separate arms with different results (21 and 4), which cannot both be right; we have not corrected it.

the proportion of participants who were "evaluated moderate or excellent" was greater in each of the seven active treatment groups when compared with placebo (57%): doxylamine/pyridoxine/dicylcomine (14% absolute difference versus placebo; 95% CI: 4 to 24), doxylamine/pyridoxine (21; 95% CI 11 to 30)

A systematic review of antihistamines and birth defects called the literature generally reassuring while flagging unconfirmed positive signals from a few large studies. (Source 45)

• Systematic review, Low certainty.
• Size: Peer-reviewed epidemiological literature published through February 2014.
• Who: Pregnancies exposed to H1- or H2-receptor antagonists.
• How long: Literature to February 2014.
• Result: No pooled estimate; narrative appraisal only.
• Funding: Authors are at the US CDC; funding not stated in the abstract.

Limit of this finding: This review deliberately excluded pyridoxine-plus-doxylamine papers published before 2001, so it is not an assessment of Bendectin or Diclegis. The quote is from the Expert Opinion section, which is the authors' interpretation, not a measured result.

The literature on the safety of antihistamine use during pregnancy with respect to birth defects is generally reassuring though the positive findings from a few large studies warrant corroboration in other populations.

The only randomised doxylamine insomnia trial we could reach compared two doxylamine brands against each other with no placebo arm, and found no difference between them. (Source 46)

• Randomized trial, Very low certainty.
• Size: 60 patients at 6 centres.
• Who: Patients aged 30 to 59 with short-term insomnia.
• How long: Short-term; duration not stated in the abstract.
• Result: Clinical remission in the majority of both groups; insomnia severity, sleep quality and daytime sleepiness improved in both; no significant between-group difference in efficacy.
• Funding: Not stated in the abstract; the trial compares two branded doxylamine products.

Limit of this finding: With no placebo arm, a trial of brand against brand cannot show that doxylamine works; it can only show the two products behave alike. The English abstract omits a detail its own Russian abstract gives, that the study was OPEN, so it was unblinded; 60 patients across six centres, about 30 per arm. The abstract does not state the treatment duration. Russian-language publication read through its English abstract only.

No significant differences between the groups in terms of clinical efficacy were found.

Where the research disagrees

Whether doxylamine with pyridoxine has a clinically meaningful effect on nausea and vomiting of pregnancy

• Koren and colleagues, the trial investigators, and the FDA label, Randomised double-blind placebo-controlled trial, 256 women analysed, 14 days: Diclectin use resulted in a significantly larger improvement in symptoms of nausea and vomiting of pregnancy compared with placebo based on both the pregnancy unique quantification of emesis score (-4.8 ± 2.7 vs -3.9 ± 2.6; P = .006) and quality of life. (Source 2)
• Persaud and colleagues, reanalysing the same patient-level data from the clinical study report, Reanalysis of the same randomised trial's individual participant data, obtained from Health Canada: the magnitude of the difference suggests that there is no clinically important benefit employing the prespecified minimal clinically important difference or "expected difference" of 3 points. (Source 34)

Whether food affects doxylamine absorption

• The FDA label for the delayed-release pregnancy combination, Label position citing a food-effect study of the delayed-release tablet: A food-effect study demonstrated that the delay in the onset of action of doxylamine succinate and pyridoxine hydrochloride may be further delayed, and a reduction in absorption may occur when tablets are taken with food (Source 7)
• Videla and colleagues, studying the plain 25 mg film-coated tablet, Randomised two-period crossover pharmacokinetic study in 24 healthy volunteers: High-fat, high-calorie food intake does not affect the kinetics of doxylamine in healthy subjects. (Source 32)

Whether a sedating first-generation antihistamine should stay on sale over the counter as a sleep aid

• Clark, Meltzer and Naclerio, writing in the World Allergy Organization Journal in 2025 about diphenhydramine, Narrative review and authors’ recommendation, about diphenhydramine rather than doxylamine; no new measurements: Based on a comprehensive evaluation of practice patterns and the prevalence and incidence of adverse clinical events, we believe that diphenhydramine has reached the end of its life cycle, and in its class of therapies it is a relatively greater public health hazard. We recommend it should no longer be widely prescribed or continue to be readily available over the counter. (Source 47)
• Melnikov and colleagues, reporting a multicentre randomised Russian doxylamine trial in 2017, Open multicentre randomised comparison of two doxylamine products with no placebo arm, 60 patients across six centres: Short-term doxylamine intake causes significant positive clinical effect in short-term insomnia with satisfactory acceptability by patients. (Source 48)

How much

• Reference intake: Dosing is set by the prescriber or, for the over-the-counter sleep aid, by the package. As a position, the prescription label effective 2026-08-24 directs two 10 mg/10 mg delayed-release tablets at bedtime on Day 1, titrated up to three or four tablets daily if symptoms persist. The over-the-counter sleep aid label directs one 25 mg tablet 30 minutes before bed, once daily. No reference intake exists because doxylamine is a drug, not a nutrient. (Source 13)
• Upper limit: As a position, the prescription label states a maximum of four tablets daily (40 mg doxylamine succinate with 40 mg pyridoxine). The over-the-counter sleep aid label sets one 25 mg tablet once daily and says not to use it with any other product containing doxylamine. No tolerable upper intake level exists because this is a drug. (Source 13)
• Studied: The pivotal pregnancy trial gave 10 mg doxylamine succinate with 10 mg pyridoxine hydrochloride as a delayed-release tablet, two to four tablets daily by a titration protocol, for 14 days; 19% stayed on 2 tablets, 21% took 3 and 60% took 4. (Source 30)
• Studied: The head-to-head trial against ondansetron gave 25 mg pyridoxine plus 12.5 mg doxylamine for 5 days. (Source 38)
• Studied: The food-effect pharmacokinetic study gave a single oral dose of doxylamine hydrogen succinate 25 mg, equivalent to 17.4 mg doxylamine base. (Source 11)
• Studied: The restored 8-way Bendectin trial instructed 2 tablets at bedtime plus 1 more in the morning or afternoon if needed, for 7 nights. (Source 44)

A common belief, and what the research shows

The belief: Bendectin was taken off the market because it was shown to cause birth defects.

What the research shows: It was withdrawn in the face of litigation, not because a study showed harm. The 1994 meta-analysis of 16 cohort and 11 case-control studies reported that the Bendectin molecule was "widely used for the treatment of nausea and vomiting of pregnancy until 1983, when production was discontinued in the face of lawsuits alleging that the drug caused congenital malformations", and found a pooled relative risk of any malformation of 0.95 (95% Cl 0.88 to 1.04), with every category-specific confidence interval including 1. The FDA label for the modern combination states that "No increased risk for congenital malformations has been reported in epidemiologic studies in pregnant women." The open question about this drug is not fetal safety but whether it works well enough to matter.

Questions and answers

What is it?

Doxylamine succinate is a medicine, not a nutrient: a first-generation sedating antihistamine of the ethanolamine group. It blocks histamine H1-receptors, and unlike newer antihistamines it passes easily into the brain. In the United States it is sold over the counter as a 25 mg night-time sleep aid and in night-time cold and flu products, and on prescription at 10 mg with 10 mg pyridoxine for nausea and vomiting of pregnancy. (Source 1)

What does it do in the body?

It blocks histamine H1-receptors in the body and, because it crosses into the brain, also dampens the arousal that brain histamine normally drives. That central effect is what makes it a sleep aid and also what causes drowsiness, poor concentration and impaired memory. Its anticholinergic action produces dry mouth, blurred vision, constipation and urinary retention. The FDA label for the pregnancy combination states that how it relieves nausea is not actually known. (Source 1)

Is it good or bad for you?

It depends entirely on who is taking it and for what. For nausea and vomiting of pregnancy its fetal safety record is one of the best studied of any drug, with a pooled relative risk of malformation of 0.95; what is disputed is whether the benefit is large enough to notice, since an independent reanalysis of the pivotal trial found no clinically important difference from placebo. For short-term sleep the evidence is preliminary and conflicting. In older adults the harms are concrete: it adds to anticholinergic burden, which is associated with delirium, falls and dementia, and sedating antihistamines impair driving more than alcohol does in simulator testing. In overdose it causes rhabdomyolysis and has killed children. (Source 34)

How do you get more of it?

There is no food or behaviour that raises it; it only enters the body as a medicine. In the United States that means an over-the-counter 25 mg sleep-aid tablet, an over-the-counter night-time cold, flu or allergy product, or a prescription 10 mg delayed-release tablet combined with pyridoxine. This is a description of how it is supplied, not a recommendation to take any of them. (Source 14)

If it is harmful, what reduces it?

In overdose, management is supportive rather than antidotal: the label describes gastric lavage or activated charcoal, whole bowel irrigation and symptomatic treatment, and points to a poison control centre. Because the prescription form is delayed-release, signs of poisoning may appear late. The case literature on doxylamine overdose adds aggressive intravenous fluids to protect the kidneys from myoglobin released by damaged muscle. (Source 26)

Why might someone be low in it or missing it?

The question does not apply in the form it takes for a nutrient. Doxylamine is not made by the body and is not present in food, so nobody is deficient in it; the only reason to have none in you is not to have taken any. What does vary is how much of a given dose reaches the blood: a review of anticholinergic drug handling reports that older adults, older women in particular, and poor CYP2D6 metabolisers reach higher concentrations from the same dose. (Source 12)

Which whole foods contain it or feed it?

No whole food contains doxylamine; it is a synthetic drug. Food matters only to absorption, and the direction depends on the formulation. A high-fat, high-calorie meal made no measurable difference to the plain 25 mg tablet in a crossover study of 24 volunteers, while the FDA label for the delayed-release pregnancy tablet says food may further delay its onset and reduce absorption, which is why that one is taken on an empty stomach. (Source 32)

What happens if you do not have it?

Nothing happens from not having doxylamine, because it is not a nutrient. Stopping it after long use is a different matter, and the evidence there is thin. A 2026 scoping review of rebound itching and hives after stopping chronic antihistamines found reports only for cetirizine and levocetirizine and none for any other antihistamine, so a doxylamine withdrawal syndrome is neither documented nor excluded. Dependence with escalating doses is documented in case reports. (Source 15)

How can you test for it?

There is no clinical test anyone needs, and no reference range to be low or high against. Doxylamine can be measured in plasma by liquid chromatography with tandem mass spectrometry, which is how pharmacokinetic studies tracked it, but that is a research assay rather than a diagnostic one. The one testing fact that matters in practice runs the other way: doxylamine can make a urine drug screen read falsely positive for methadone, opiates or PCP, so such a result needs confirmation by gas chromatography mass spectrometry. (Source 7)

References

1. Indian J Dermatol. Pharmacology of antihistamines.. 2013. PMID 23723474, DOI 10.4103/0019-5154.110832. Read the source
2. Am J Obstet Gynecol. Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial (RESULTS section of the abstract). 2010. PMID 20843504, DOI 10.1016/j.ajog.2010.07.030. Read the source
3. J Clin Sleep Med. Oral nonprescription treatment for insomnia: an evaluation of products with limited evidence (RESULTS AND CONCLUSIONS section of the abstract). 2005. PMID 17561634, DOI 10.5664/jcsm.26314. Read the source
4. Cochrane Database Syst Rev. Antihistamines for the common cold (MAIN RESULTS section of the abstract). 2015. PMID 26615034, DOI 10.1002/14651858.CD009345.pub2. Read the source
5. Allergy Asthma Clin Immunol. CSACI position statement: Newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria.. 2019. PMID 31582993, DOI 10.1186/s13223-019-0375-9. Read the source
6. Br J Dermatol. Night-time sedating H1 -antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial (RESULTS section of the abstract). 2014. PMID 24472058, DOI 10.1111/bjd.12846. Read the source
7. DailyMed (US National Library of Medicine), SPL effective 2026-08-24. Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets, FDA prescribing information: Drug Interactions (7.1-7.3) sections, in full. 2026. Read the source
8. Ann Intern Med. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator (RESULTS section of the abstract). 2000. PMID 10691585, DOI 10.7326/0003-4819-132-5-200003070-00004. Read the source
9. DailyMed (US National Library of Medicine), SPL effective 2026-08-24. Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets, FDA prescribing information: Contraindications (4) and Warnings and Precautions (5.1-5.3) sections, in full. 2026. Read the source
10. Drugs Aging. Drugs Contributing to Anticholinergic Burden and Risk of Fall or Fall-Related Injury among Older Adults with Mild Cognitive Impairment, Dementia and Multiple Chronic Conditions: A Retrospective Cohort Study (RESULTS section of the abstract). 2019. PMID 30652263, DOI 10.1007/s40266-018-00630-z. Read the source
11. Drugs R D. Food effects on the pharmacokinetics of doxylamine hydrogen succinate 25 mg film-coated tablets: a single-dose, randomized, two-period crossover study in healthy volunteers (RESULTS section of the abstract). 2012. PMID 23230999, DOI 10.2165/11641640-000000000-00000. Read the source
12. Pharmacol Res Perspect. The role of sex, age and genetic polymorphisms of CYP enzymes on the pharmacokinetics of anticholinergic drugs.. 2021. PMID 34003603, DOI 10.1002/prp2.775. Read the source
13. DailyMed (US National Library of Medicine), SPL effective 2026-08-24. Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets, FDA prescribing information: Indications and Usage (1) and Dosage (2.1) sections, in full. 2026. Read the source
14. DailyMed (US National Library of Medicine), SPL effective 2026-09-01. Nighttime Sleep-Aid (doxylamine succinate 25 mg) tablet, marketed as Kroger 44-386, OTC Drug Facts label: all Drug Facts content sections including the parent Warnings heading, excluding the principal display panel. 2026. Read the source
15. Clin Exp Allergy. Rebound Pruritus and Urticaria After Discontinuation of Chronic Antihistamine Use-A Scoping Review (RESULTS section of the abstract). 2026. PMID 41911848, DOI 10.1111/cea.70291. Read the source
16. Clin Exp Allergy. Rebound Pruritus and Urticaria After Discontinuation of Chronic Antihistamine Use-A Scoping Review (CONCLUSIONS section of the abstract). 2026. PMID 41911848, DOI 10.1111/cea.70291. Read the source
17. Turk Psikiyatri Derg. Doxylamine Addiction: A Case Report.. 2022. PMID 36148572, DOI 10.5080/u26340. Read the source
18. DailyMed (US National Library of Medicine), SPL effective 2026-08-24. Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets, FDA prescribing information: Adverse Reactions (6, 6.1, 6.2) sections, in full, with Table 1 rebuilt row by row from the SPL XML with its own column headings. 2026. Read the source
19. Ann Intern Med. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator (CONCLUSIONS section of the abstract). 2000. PMID 10691585, DOI 10.7326/0003-4819-132-5-200003070-00004. Read the source
20. JAMA Intern Med. Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study (RESULTS section of the abstract). 2019. PMID 31233095, DOI 10.1001/jamainternmed.2019.0677. Read the source
21. JAMA Intern Med. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study (RESULTS section of the abstract). 2015. PMID 25621434, DOI 10.1001/jamainternmed.2014.7663. Read the source
22. J Am Geriatr Soc. Association of Inpatient Prescribing of First-Generation Antihistamines With Delirium in Older Adults: A Cross-Sectional Study (RESULTS section of the abstract). 2025. PMID 41121962, DOI 10.1111/jgs.70121. Read the source
23. Hum Exp Toxicol. Risk factors for rhabdomyolysis following doxylamine overdose.. 2007. PMID 17884948, DOI 10.1177/0960327107077507. Read the source
24. Am J Emerg Med. The associative factors of delayed-onset rhabdomyolysis in patients with doxylamine overdose (RESULTS section of the abstract). 2011. PMID 21159475, DOI 10.1016/j.ajem.2010.10.032. Read the source
25. Cureus. When Overdose of Doxylamine Leads to Severe Rhabdomyolysis and Renal Failure That Requires Hemodialysis: A Case Report and Literature Review.. 2023. PMID 37581198, DOI 10.7759/cureus.43395. Read the source
26. DailyMed (US National Library of Medicine), SPL effective 2026-08-24. Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets, FDA prescribing information: Pediatric Use (8.4) and Overdosage (10.1, 10.2) sections, in full. 2026. Read the source
27. Curr Neuropharmacol. Over-the-counter Psychosis: A Systematic Review of the Misuse of Antihistamines, Cough Medicines, and Decongestants and the Risk of Developing Psychosis (RESULTS section of the abstract). 2025. PMID 39976040, DOI 10.2174/011570159X344365250114064248. Read the source
28. Cochrane Database Syst Rev. Oral antihistamine-decongestant-analgesic combinations for the common cold (MAIN RESULTS section of the abstract). 2022. PMID 35060618, DOI 10.1002/14651858.CD004976.pub4. Read the source
29. J Pediatr Pharmacol Ther. The Use and Safety of Cough and Cold Medications in the Pediatric Population.. 2025. PMID 39935563, DOI 10.5863/1551-6776-30.1.17. Read the source
30. DailyMed (US National Library of Medicine), SPL effective 2026-08-24. Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets, FDA prescribing information: Mechanism of Action (12.1) and Clinical Studies (14) sections, in full, with Table 6 rebuilt row by row from the SPL XML with its own column headings. 2026. Read the source
31. Teratology. Bendectin and birth defects: I. A meta-analysis of the epidemiologic studies.. 1994. PMID 7974252, DOI 10.1002/tera.1420500105. Read the source
32. Drugs R D. Food effects on the pharmacokinetics of doxylamine hydrogen succinate 25 mg film-coated tablets: a single-dose, randomized, two-period crossover study in healthy volunteers (CONCLUSION section of the abstract). 2012. PMID 23230999, DOI 10.2165/11641640-000000000-00000. Read the source
33. PLoS One. Doxylamine-pyridoxine for nausea and vomiting of pregnancy randomized placebo controlled trial: Prespecified analyses and reanalysis (METHODS AND FINDINGS section of the abstract). 2018. PMID 29342163, DOI 10.1371/journal.pone.0189978. Read the source
34. PLoS One. Doxylamine-pyridoxine for nausea and vomiting of pregnancy randomized placebo controlled trial: Prespecified analyses and reanalysis (CONCLUSIONS section of the abstract). 2018. PMID 29342163, DOI 10.1371/journal.pone.0189978. Read the source
35. PLoS One. 8-Way Randomized Controlled Trial of Doxylamine, Pyridoxine and Dicyclomine for Nausea and Vomiting during Pregnancy: Restoration of Unpublished Information (CONCLUSION section of the abstract). 2017. PMID 28052111, DOI 10.1371/journal.pone.0167609. Read the source
36. Cochrane Database Syst Rev. Interventions for nausea and vomiting in early pregnancy (MAIN RESULTS section of the abstract). 2015. PMID 26348534, DOI 10.1002/14651858.CD007575.pub4. Read the source
37. Cochrane Database Syst Rev. Interventions for nausea and vomiting in early pregnancy (AUTHORS' CONCLUSIONS section of the abstract). 2015. PMID 26348534, DOI 10.1002/14651858.CD007575.pub4. Read the source
38. Obstet Gynecol. Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial (RESULTS section of the abstract). 2014. PMID 25198265, DOI 10.1097/AOG.0000000000000479. Read the source
39. BMC Medicine. Antiemetic use during pregnancy and child neurodevelopment: population-based birth cohort study (RESULTS section of the abstract). 2025. PMID 41327197, DOI 10.1186/s12916-025-04497-x. Read the source
40. BMC Pregnancy Childbirth. Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial (RESULTS section of the abstract). 2015. PMID 25884778, DOI 10.1186/s12884-015-0488-1. Read the source
41. Br J Dermatol. Night-time sedating H1 -antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial (CONCLUSIONS section of the abstract). 2014. PMID 24472058, DOI 10.1111/bjd.12846. Read the source
42. Cochrane Database Syst Rev. Antihistamines for the common cold (AUTHORS' CONCLUSIONS section of the abstract). 2015. PMID 26615034, DOI 10.1002/14651858.CD009345.pub2. Read the source
43. Cochrane Database Syst Rev. Oral antihistamine-decongestant-analgesic combinations for the common cold (AUTHORS' CONCLUSIONS section of the abstract). 2022. PMID 35060618, DOI 10.1002/14651858.CD004976.pub4. Read the source
44. PLoS One. 8-Way Randomized Controlled Trial of Doxylamine, Pyridoxine and Dicyclomine for Nausea and Vomiting during Pregnancy: Restoration of Unpublished Information (RESULTS section of the abstract). 2017. PMID 28052111, DOI 10.1371/journal.pone.0167609. Read the source
45. Expert Opin Drug Saf. Antihistamines and birth defects: a systematic review of the literature (EXPERT OPINION section of the abstract). 2014. PMID 25307228, DOI 10.1517/14740338.2014.970164. Read the source
46. Zh Nevrol Psikhiatr Im S S Korsakova. [Effectiveness of reslip (doxylamine) in short-term insomnia: multicenter comparative randomized study] (RESULTS section of the abstract). 2017. PMID 28777365, DOI 10.17116/jnevro20171174256-59. Read the source
47. World Allergy Organ J. Diphenhydramine: It is time to say a final goodbye.. 2025. PMID 39925982, DOI 10.1016/j.waojou.2025.101027. Read the source
48. Zh Nevrol Psikhiatr Im S S Korsakova. [Effectiveness of reslip (doxylamine) in short-term insomnia: multicenter comparative randomized study] (CONCLUSION section of the abstract). 2017. PMID 28777365, DOI 10.17116/jnevro20171174256-59. Read the source